Last reviewed · How we verify

NCT03649009

Thiamine As An Adjuvant Therapy For Hyperlactatemia In Septic Shock Patients

Status unknown NA Last updated 31 August 2018
What this trial tests

NA trial testing Normal Saline in Hyperlactatemia in 72 participants. Status unknown.

Timeline
1 January 2018
Primary endpoint
1 December 2018
31 March 2019

Quick facts

Lead sponsorUniversiti Kebangsaan Malaysia Medical Centre
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment72
Start date1 January 2018
Primary completion1 December 2018
Estimated completion31 March 2019
Sites1 location across Malaysia

Drugs / interventions tested

Conditions studied

Sponsor

Universiti Kebangsaan Malaysia Medical Centre — full company profile →

Who can join

18 and older, any sex, with Hyperlactatemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aimed to assess the effectiveness of intravenous thiamine as compared with placebo in reducing the lactate level in septic shock patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Normal Saline

Trials testing the same drug.

Other recruiting trials for Hyperlactatemia

Currently open trials in the same condition.

Other Universiti Kebangsaan Malaysia Medical Centre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03649009.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing